Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Journal of Endocrinological Investigation
Erschienen in: Journal of Endocrinological Investigation 2/2014

01.02.2014 | Review

Pituitary tumors and pregnancy: the interplay between a pathologic condition and a physiologic status

verfasst von: Rosario Pivonello, Maria Cristina De Martino, Renata S. Auriemma, Carlo Alviggi, Ludovica F. S. Grasso, Alessia Cozzolino, Monica De Leo, Giuseppe De Placido, Annamaria Colao, Gaetano Lombardi

Erschienen in: Journal of Endocrinological Investigation | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Pregnancy is becoming a relatively common event in patients with pituitary tumors (PT), due to the increasing availability of medical treatments, which control pituitary diseases associated with the development of PT. However, the presence of PT and its treatment may be a disturbing factor for pregnancy, and pregnancy significantly influences the course and the management of PT. This review summarizes the knowledge about the management of PT during pregnancy and the occurrence of pregnancy in patients with pre-existent PT, focusing on secreting PT characterized by hormonal excess and on clinically non-functioning PT often associated to hormone deficiency, which configure the hypopituitaric syndrome.
Literatur
1.
Scheithauer BW, Sano T, Kovacs KT, Young WF Jr, Ryan N, Randall RV (1990) The pituitary gland in pregnancy. A clinicopathologic and immunohistochemical study of 69 cases. Mayo Clin Proc 65:461–474PubMedCrossRef
2.
Melmed S, Polonsky KS, Larsen PR, Kronenberg HM (eds) (2011) Williams textbook of endocrinology, 12th edn. Saunders Elsevier, Philadelphia
3.
Molitch ME (2003) Pituitary tumors and pregnancy. GH IGF Res 13:S38–S44
4.
Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML, McCutcheon IE (2004) The prevalence of pituitary adenomas: a systematic review. Cancer 101(3):613–619PubMedCrossRef
5.
Beckers A, Daly AF (2007) The clinical, pathological, and genetic features of familial isolated pituitary adenomas. Eur J Endocrinol 157(4):371–382PubMedCrossRef
6.
Moertini P, Losa M, Barzaghi R, Boari N, Giovanelli M (2005) Results of transsphenoidal surgery in a large series of patients with pituitary adenoma. Neurosurgery 56(6):1222–1233CrossRef
7.
Hirshfeld-Cytron J, Kim HH (2006) Treatment of fertility in women with pituitary tumors. Expert Rev Anticancer Ther 6(9 Suppl):s55–s62PubMedCrossRef
8.
Chandrashekar V, Zaczek D, Bartke A (2004) The consequences of altered somatotropic system on reproduction. Biol Reprod 71(1):17–27PubMedCrossRef
9.
Levy J (1995) Endogenous plasma GH and the occurrence of pregnancies in patients undergoing in vitro fertilization and embryo transfer with ovarian stimulation. Human Reprod 10:1065–1069
10.
Chrousos GP, Torpy DJ, Gold PW (1998) Interactions between the hypothalamic–pituitary–adrenal axis and the female reproductive system: clinical implications. Ann Int Med 129(3):229–240PubMedCrossRef
11.
Cooke PS, Holsberger DR, Witorsch RJ, Sylvester PW, Meredith JM, Treinen KA, Chapin RE (2004) Thyroid hormone, glucocorticoids, and prolactin at the nexus of physiology, reproduction, and toxicology. Toxicol Appl Pharmacol 194:309–335PubMedCrossRef
12.
Poppe K, Velkeniers B, Glinoer D (2007) Thyroid disease and female reproduction. Clin Endocrinol (Oxf) 66(3):309–321CrossRef
13.
Dinc H, Esen F, Demirci A, Sari A, Resit Gumele H (1998) Pituitary dimensions and volume measurements in pregnancy and post partum. MR assessment. Acta Radiol 39:64–69PubMed
14.
Elster AD, Sanders TG, Vines FS, Chen MY (1991) Size and shape of the pituitary gland during pregnancy and post partum: measurement with MR imaging. Radiology 181:531–535PubMed
15.
Gonzalez JG, Elizondo G, Saldivar D, Nanez H, Todd LE, Villarreal JZ (1988) Pituitary gland growth during normal pregnancy: an in vivo study using magnetic resonance imaging. Am J Med 85:217–220PubMedCrossRef
16.
Waters MJ, Kaye PL (2002) The role of growth hormone in fetal development. Growth Hormon IGF Res 12:137–146CrossRef
17.
Frankenne F, Closset J, Gomez F, Scippo ML, Smal J, Hennen G (1988) The physiology of growth hormones (GHs) in pregnant women and partial characterization of the placental GH variant. J Clin Endocrinol Metab 66:1171–1180PubMedCrossRef
18.
Eriksson L, Frankenne F, Eden S, Hennen G, Von Schoultz B (1989) Growth hormone 24-h serum profiles during pregnancy lack of pulsatility for the secretion of the placental variant. Br J Obstet Gynaecol 106:949–953CrossRef
19.
Beckers A, Stevenaert A, Foidart J-M, Hennen G, Frankenne F (1990) Placental and pituitary growth hormone secretion during pregnancy in acromegalic women. J Clin Endocrinol Metab 71:725–731PubMedCrossRef
20.
Winter JSD (1998) Fetal and neonatal adrenocortical physiology. In: Polin RA, Fox WW (eds) Maternal–fetal endocrinology. WB Saunders, Philadelphia, pp 2447–2459
21.
Liggins GC (1994) The role of cortisol in preparing the fetus for birth. Reprod Fertil Dev 6:141–150PubMedCrossRef
22.
Pepe GJ, Albrecht ED (1990) Regulation of the primate fetal adrenal cortex. Endocr Rev 11:151–176PubMedCrossRef
23.
Mastorakos G, Ilias I (2003) Maternal and fetal hypothalamic–pituitary–adrenal axes during pregnancy and postpartum. Ann N Y Acad Sci 997:136–149PubMedCrossRef
24.
Lindsay JR, Nieman LK (2005) The hypothalamic–pituitary–adrenal axis in pregnancy: challenges in disease detection and treatment. Endocr Rev 26(6):775–799PubMedCrossRef
25.
Lindsay JR, Jonklaas J, Oldfield EH, Nieman LK (2005) Cushing’s syndrome during pregnancy: personal experience and review of the literature. J Clin Endocrinol Metab 90(5):3077–3083PubMedCrossRef
26.
Nolten WE, Lindheimer MD, Rueckert PA, Oparil S, Ehrlich EN (1980) Diurnal patterns and regulation of cortisol secretion in pregnancy. J Clin Endocrinol Metab 51:466–472PubMedCrossRef
27.
Fisher DA, Nelson JC, Carlton EI, Wilcox RB (2000) Maturation of human hypothalamic–pituitary–thyroid function and control. Thyroid 10:229–234PubMedCrossRef
28.
Vulsma T, Gons MH, de Vijlder JJ (1989) Maternal–fetal transfer of thyroxine in congenital hypothyroidism due to a total organification defect or thyroid agenesis. N Engl J Med 321:13–16PubMedCrossRef
29.
Glinoer D, de Nayer P, Bourdoux P, Lemone M, Robyn C, van Steirteghem A, Kinthaert J, Lejeune B (1990) Regulation of maternal thyroid during pregnancy. J Clin Endocrinol Metab 71(2):276–287PubMedCrossRef
30.
31.
Kredentser JV, Hoskins CF, Scott JZ (1981) Hyperprolactinemia: a significant factor in female infertility. Am J Obstet Gynecol 139:264–267PubMed
32.
Gillam MP, Molitch ME, Lombardi G, Colao A (2006) Advances in the treatment of prolactinomas. Endocr Rev 27(5):485–534PubMedCrossRef
33.
Molitch ME (1999) Diagnosis and treatment of prolactinomas. Adv Intern Med 44:117–153PubMed
34.
Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF, The Cabergoline Comparative Study Group (1994) A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 331:904–909PubMedCrossRef
35.
Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R, Fideleff H, Hadani M, Kelly P, Kleinberg D, Laws E, Marek J, Scanlon M, Sobrinho LG, Wass JA, Giustina A (2006) Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol 65(2):265–273CrossRef
36.
Herman-Bonert V, Seliverstow M, Melmed S (1998) Pregnancy in acromegaly: successful therapeutic outcome. J Clin Endocrinol Metab 83:727–731PubMed
37.
Cozzi R, Attanasio R, Barausse M (2006) Pregnancy in acromegaly: a one-center experience. Eur J Endocrinol 155(2):279–284PubMedCrossRef
38.
Grasso LFS, Pivonello R, Auriemma RS, Galdiero M, De Leo M, Cozzolino A, Vitale P, Simeoli C, Lombardi G, Colao A (2010) Acromegaly and women fertility. Minerva Endocrinol 35(4):13–26
39.
Beuscher MA, McClamrock HD, Adashi EY (1992) Cushing’s syndrome in pregnancy. Obstet Gynecol 79:130–137
40.
Benoit R, Pearson-Murphy BE, Robert F, Marcovitz S, Hardy J, Tsoukas G, Gardiner RJ (1980) Hyperthyroidism due to a pituitary TSH secreting tumour with amenorrhoea-galactorrhoea. Clin Endocrinol 12(1):11–19CrossRef
41.
Kupersmith MJ, Rosenberg C, Kleinberg D (1994) Visual loss in pregnant women with pituitary adenomas. Ann Intern Med 121:473–477PubMedCrossRef
42.
43.
Colao A, Di Sarno A, Landi ML, Cirillo S, Sarnacchiaro F, Facciolli G, Pivonello R, Cataldi M, Merola B, Annunziato L, Lombardi G (1997) Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab 82:3574–3579PubMedCrossRef
44.
Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R, Volpe R, Di Salle F, Cirillo S, Annunziato L, Lombardi G (2000) Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab 85:2247–2252PubMed
45.
Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, Di Somma C, Faggiano A, Lombardi G, Colao A (2001) Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab 86:5256–5261PubMedCrossRef
46.
Di Sarno A, Landi ML, Marzullo P, Di Somma C, Pivonello R, Cerbone G, Lombardi G, Colao A (2000) The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Clin Endocrinol 53:53–60CrossRef
47.
48.
49.
Musolino NR, Bronstein MD (2001) Prolactinomas and pregnancy. In: Bronstein MD (ed) Pituitary tumors and pregnancy. Kluwer Academic Publishers, Norwell, pp 91–108CrossRef
50.
Auriemma RS, Perone Y, Di Sarno A, Grasso LFS, Guerra E, Gasperi M, Pivonello R, Colao A (2013) Results of a single-center observational 10-year survey study on recurrence of hyperprolactinemia after pregnancy and lactation. J Clin Endocrinol Metab 98:372–379PubMedCrossRef
51.
Krupp P, Monka C, Richter K (1988) The safety aspects of infertility treatments. In: Proceedings of the second world congress of gynecology and obstetrics, Rio de Janeiro, p 9
52.
Konopka P, Raymond JP, Merceron RE, Seneze J (1983) Continuous administration of bromocriptine in the prevention of neurological complications in pregnant women with prolactinomas. Am J Obstet Gynecol 146(8):935–938PubMed
53.
Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B, Mockel J, Lamberigts G, Petrossians P, Coremans P, Mahler C, Stevenaert A, Verlooy J, Raftopoulos C, Beckers A (1999) Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 84:2518–2522PubMedCrossRef
54.
Colao A, Abs R, Bárcena DG, Chanson P, Paulus W, Kleinberg DL (2008) Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study. Clin Endocrinol (Oxf) 68(1):66–71 Epub 2007 Aug 29CrossRef
55.
Ricci E, Parazzini F, Motta T, Ferrari CI, Colao A, Clavenna A, Rocchi F, Gangi E, Paracchi S, Gasperi M, Lavezzari M, Nicolosi AE, Ferrero S, Landi ML, Beck-Peccoz P, Bonati M (2002) Pregnancy outcome after cabergoline treatment in early weeks of gestation. Reprod Toxicol 16:791–793PubMedCrossRef
56.
Robert E, Musatti L, Piscitelli G, Ferrari CI (1996) Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod Toxicol 10:333–337PubMedCrossRef
57.
Molitch ME (2011) Prolactinoma in pregnancy. Best Pract Res Clin Endocrinol Metab 25(6):885–889PubMedCrossRef
58.
Ono M, Miki N, Amano K, Kawamata T, Seki T, Makino R, Takano K, Izumi S, Okada Y, Hori T (2010) Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas. J Clin Endocrinol Metab 95(6):2672–2679PubMedCrossRef
59.
Lebbe M, Hubinont C, Bernard P, Maiter D (2010) Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women. Clin Endocrinol (Oxf) 73(2):236–242
60.
Stalldecker G, Mallea-Gil MS, Guitelman M, Alfieri A, Ballarino MC, Boero L, Chervin A, Danilowicz K, Diez S, Fainstein-Day P, García-Basavilbaso N, Glerean M, Gollan V, Katz D, Loto MG, Manavela M, Rogozinski AS, Servidio M, Vitale NM (2010) Effects of cabergoline on pregnancy and embryo-fetal development: retrospective study on 103 pregnancies and a review of the literature. Pituitary 13(4):345–350PubMedCrossRef
61.
De Mari M, Zenzola A, Lamberti P (2002) Antiparkinsonian treatment in pregnancy. Mov Disord 17:428–429PubMedCrossRef
62.
Acharya V (2004) Review of pregnancy reports in patients on pergolide treatment. Eli Lilly Co., Indianapolis
63.
Webster J (1996) A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Drug Saf 14(4):228–238PubMedCrossRef
64.
Brodsky JB, Cohen EN, Brown BW Jr, Wu ML, Whitcher C (1980) Surgery during pregnancy and fetal outcome. Am J Obstet Gynecol 138:1165–1167PubMed
65.
Rossi AM, Vilska S, Heinonen PK (1995) Outcome of pregnancies in women with treated or untreated hyperprolactinemia. Eur J Obstet Gynecol Reprod Biol 63:143–146PubMedCrossRef
66.
Crosignani PG, Mattei AM, Scarduelli C, Cavioni V, Boracchi P (1989) Is pregnancy the best treatment for hyperprolactinemia? Hum Reprod 4(8):910–912PubMed
67.
Ikegami H, Aono T, Koizumi K, Koike K, Fukui H, Tanizawa O (1987) Relationship between the methods of treatment for prolactinomas and the puerperal lactation. Fertil Steril 47(5):867–869PubMed
68.
Molitch ME (2006) Pituitary disorders during pregnancy. Endocrinol Metab Clin North Am 35:99–116PubMedCrossRef
69.
Colao A, Ferone D, Marzullo P, Lombardi G (2004) Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25:102–152PubMedCrossRef
70.
71.
van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA, Thorner MO (2001) Long term treatment of acromegaly with pegvisomant, a growth hormone antagonist. Lancet 358:1754–1759PubMedCrossRef
72.
Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M, Briganti F, Tortora F, Burman P, Kourides IA, Strasburger CJ, Lombardi G (2006) Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol 154(3):467–477PubMedCrossRef
73.
Atmaca A, Dagdelen S, Erbas T (2006) Follow-up of pregnancy in acromegalic women: different presentations and outcomes. Exp Clin Endocrinol Diabetes 114(3):135–139PubMedCrossRef
74.
Colao A, Ferone D, Marzullo P, Di Sarno A, Cerbone G, Sarnacchiaro F, Cirillo S, Merola B, Lombardi G (1997) Effect of different dopaminergic agents in the treatment of acromegaly. J Clin Endocrinol Metab 82:518–523PubMedCrossRef
75.
Blackhurst G, Strachan MW, Collie D, Gregor A, Statham PF, Seckl JE (2002) The treatment of a thyrotropin-secreting pituitary macroadenoma with octreotide in twin pregnancy. Clin Endocrinol (Oxf) 57:401–404CrossRef
76.
Boulanger C, Vezzosi D, Bennet A, Lorenzini F, Fauvel J, Caron P (2004) Normal pregnancy in a woman with nesidioblastosis treated with somatostatin analog octreotide. J Endocrinol Invest 27(5):465–470PubMedCrossRef
77.
Caron P, Gerbeau C, Pradayrol L, Simonetta C, Bayard F (1996) Successful pregnancy in an infertile woman with a thyrotropin-secreting macroadenoma treated with somatostatin analog (octreotide). J Clin Endocrinol Metab 81:1164–1168PubMed
78.
Brian SR, Bidlingmaier M, Wajnrajch MP, Weinzimer SA, Inzucchi SE (2007) Treatment of acromegaly with pegvisomant during pregnancy: maternal and fetal effects. J Clin Endocrinol Metab 92(9):3374–3377PubMedCrossRef
79.
Cheng V, Faiman C, Kennedy L, Khoury F, Hatipoglu B, Weil R, Hamrahian A (2012) Pregnancy and acromegaly: a review. Pituitary 15:59–63PubMedCrossRef
80.
Maffei P, Tamagno G, Nardelli GB, Milan G, Martini C, DeCarlo E, Dassie F, Vettor R, Sicolo N (2010) Treatment with somatostatin analogs in acromegalic women during pregnancy. Minerva Endocrinol 35(4):49–69
81.
Caron P, Broussaud S, Bertherat J, Borson-Chazot F, Brue T, Cortet-Rudelli C, Chanson P (2010) Acromegaly and pregnancy: a retrospective multicenter study of 59 pregnancies in 46 women. J Clin Endocrinol Metab 95:4680–4687PubMedCrossRef
82.
Cheng S, Grasso LFS, Martinez-Orozco JA, Al-Agha R, Pivoenllo R, Colao A, Ezzat S (2012) Pregnancy in acromegaly: experience from two referral centers and systematic review of literature. Clin Endocrinol 76:264–271CrossRef
83.
Melmed S, Casanueva FF, Klibanski A, Bronstein MD, Chanson P, Lamberts SW, Strasburger CJ, Wass JAH, Giustina A (2013) A consensus on the diagnosis and treatment of acromegaly complications. Pituitary 16:294–302PubMedCentralPubMedCrossRef
84.
Bevan JS, Gough MH, Gillmer MD, Burke CW (1987) Cushing’s syndrome in pregnancy: the timing of definitive treatment. Clin Endocrinol 27(2):225–233CrossRef
85.
Aron DC, Schnall AM, Sheeler LR (1990) Cushing’s syndrome and pregnancy. Am J Obstet Gynecol 162:244–252PubMedCrossRef
86.
Pivonello R, De Martino MC, De Leo M, Lombardi G, Colao A (2008) Cushing’s syndrome. Endocrinol Metab Clin North Am 37(1):135–149PubMedCrossRef
87.
Chico A, Manzanares JM, Halperin I, Martonez de Osaba MJ, Adelantado J, Webb SM (1996) Cushing’s disease and pregnancy. Eur J Obstet Gynecol Reprod Biol 64:143–146PubMedCrossRef
88.
Guilhaume B, Sanson ML, Billaud L, Bertagna X, Laudat MH, Luton JP (1992) Cushing’s syndrome and pregnancy: aetiologies and prognosis in twenty-two patients. Eur J Med 1(2):83–89PubMed
89.
Lekarev O, New MI (2011) Adrenal disease in pregnancy. Best Pract Res Clin Endocrinol Metab 25(6):959–973PubMedCrossRef
90.
Beck-Peccoz P, Brucker-Davis F, Persani L, Smallridge RC, Weintraub BD (1996) Thyrotropin-secreting pituitary tumors. Endocr Rev 17(6):610–638PubMed
91.
Brucker-Davis F, Oldfield EH, Skarulis MC, Doppman JL, Weintraub BD (1999) Thyrotropin-secreting pituitary tumors: diagnostic criteria, thyroid hormone sensitivity, and treatment outcome in 25 patients followed at the National Institutes of Health. J Clin Endocrinol Metab 84(2):476–486PubMedCrossRef
92.
Chaiamnuay S, Moster M, Katz MR, Kim YN (2003) Successful management of a pregnant woman with a TSH secreting pituitary adenoma with surgical and medical therapy. Pituitary 6(2):109–113PubMedCrossRef
93.
Murata Y, Ando H, Nagasaka T, Takahashi I, Saito K, Fukugaki H, Matsuzawa K, Mizutani S (2003) Successful pregnancy after bromocriptine therapy in an anovulatory woman complicated with ovarian hyperstimulation caused by follicle-stimulating hormone-producing plurihormonal pituitary microadenoma. J Clin Endocrinol Metab 88(5):1988–1993PubMedCrossRef
94.
Metadaten
Titel
Pituitary tumors and pregnancy: the interplay between a pathologic condition and a physiologic status
verfasst von
Rosario Pivonello
Maria Cristina De Martino
Renata S. Auriemma
Carlo Alviggi
Ludovica F. S. Grasso
Alessia Cozzolino
Monica De Leo
Giuseppe De Placido
Annamaria Colao
Gaetano Lombardi
Publikationsdatum
01.02.2014
Verlag
Springer International Publishing
Erschienen in
Journal of Endocrinological Investigation / Ausgabe 2/2014
Elektronische ISSN: 1720-8386
DOI
https://doi.org/10.1007/s40618-013-0019-8

Weitere Artikel der Ausgabe 2/2014

Journal of Endocrinological Investigation 2/2014 Zur Ausgabe

Original Article

Frequency and effect on serum TSH of phosphodiesterase 8B (PDE8B) gene polymorphisms in patients with sporadic nonautoimmune subclinical hypothyroidism

Original Article

The role of TNF-α G-308A promoter polymorphism in glycemic control in Type 2 diabetes patients

Rapid Communication

Impact of short-term treatment with benzodiazepines and imidazopyridines on glucose metabolism in healthy subjects

Original Article

Pre-treatment circulating leptin/ghrelin ratio as a non-invasive marker to identify patients likely to regain the lost weight after an energy restriction treatment

Original Article

Serum interferon gamma concentration is associated with bone mineral density in overweight boys

Original Article

Serum galectin-3 levels in women with PCOS

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Metformin rückt in den Hintergrund

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

24.04.2024 | DGIM 2024 | Nachrichten

Bei Senioren mit Prostatakarzinom auf Anämie achten!
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise